Cardionomic

Cardionomic, headquartered in Minneapolis, is dedicated to transforming the treatment of Acute Decompensated Heart Failure (ADHF). The company is investigating the Cardiac Pulmonary Nerve Stimulation (CPNS™) System, which involves placing a CPNS Catheter in the right pulmonary artery to provide temporary, targeted electrical stimulation to the surrounding nerves. Cardionomic has completed enrollment in both the STIM-ADHF and STOP-ADHF pilot studies. The STOP-ADHF Study assessed the safety and performance of the CPNS System in patients hospitalized for ADHF across the United States, the European Union, and Panama, while the STIM-ADHF Study focused on patients in the European Union. Additionally, the CPNS 2 Feasibility Study evaluated the short-term safety and feasibility of the CPNS System over 1-3 hours in patients with chronic heart failure. In October 2015, Cardionomic raised $20 million in Series A financing. The CPNS System has shown the ability to reproducibly increase contractility without affecting heart rate. The first U.S. patient was enrolled in the CPNS Pilot Study at The Ohio State University Wexner Medical Center. Cardionomic collaborates with healthcare partners to develop effective treatments for heart failure and has conducted clinical studies in multiple countries, including the United States, Slovakia, and Panama. With over 25 million people worldwide suffering from heart failure and 5 million hospitalized annually, Cardionomic is committed to advancing clinical evidence and publications related to their research and studies.